Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Rhea-AI Summary

Azitra (NYSE: AZTR) announced cancellation of its special meeting of stockholders that had been originally scheduled for February 6, 2026 and adjourned to March 6, 2026 due to a lack of quorum.

The company is a clinical‑stage biopharmaceutical developer of engineered S. epidermidis programs, including ATR-12 (Phase 1b for Netherton syndrome) and ATR-04 (FDA Fast Track for EGFRi associated rash; open IND). Azitra’s platform includes ~1,500 bacterial strains and AI/ML screening tools.

News Market Reaction – AZTR

+2.50%

7 alerts

+2.50% Session close to close

-17.5% Trough in 4 hr 35 min

$3.31M Market Cap

0.6x Rel. Volume

In the Mar 6 session, AZTR gained 2.50%, reflecting a moderate positive market reaction. Argus tracked a trough of -17.5% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement cancels Azitra’s 2026 special stockholder meeting, which had been tied to proposal...

Analysis

This announcement cancels Azitra’s 2026 special stockholder meeting, which had been tied to proposals allowing issuance of more than 19.99% of outstanding common shares. It follows earlier adjournments due to lack of quorum but does not change the company’s clinical programs, including ATR-12 and ATR-04, or its previously disclosed financial position. Investors may focus on future updates regarding capital strategy, trial milestones, and any revised plans for stockholder approvals.

Key Figures

Phase 1b trial: Phase 1b Phase 1/2 trial: Phase 1/2 EGFRi rash population: 150,000 people +5 more

8 metrics

Phase 1b trial Phase 1b ATR-12 in adult Netherton syndrome patients

Phase 1/2 trial Phase 1/2 ATR-04 for EGFR inhibitor–associated rash

EGFRi rash population 150,000 people U.S. patients impacted by EGFRi-associated rash

Microbial library size 1,500 bacterial strains Proprietary microbial library in Azitra’s platform

Current share price $0.1787 Price before this governance-focused news

52-week high $2.664 Pre-news 52-week high level

52-week low $0.153 Pre-news 52-week low level

Market cap $2,034,288 Pre-news equity value indication

Historical Context

5 past events · Latest: Feb 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 27	Earnings and update	Neutral	-6.1%	Full-year 2025 results with clinical progress but continued losses and low cash.
Feb 24	Clinical site added	Positive	+2.7%	MD Anderson added as clinical site for Phase 1/2 ATR-04 EGFRi rash trial.
Feb 19	Conference presentation	Neutral	+7.2%	BIO Investment & Growth Summit presentation and investor meetings in Miami.
Feb 06	Special meeting delay	Negative	-3.4%	Adjourned special meeting on approval to issue >19.99% new shares due to no quorum.
Jan 07	Investor conference	Neutral	+6.8%	Biotech Showcase presentation and one-on-one investor and partner meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows mixed reactions: clinical and operational updates sometimes produced gains, while financing/governance and earnings-related items tended to coincide with pressure on the stock.

Recent Company History

Over the last few months, Azitra has combined pipeline progress with acute financing and governance challenges. Earnings on Feb 27, 2026 highlighted ongoing losses and limited cash, while a special meeting tied to issuing over 19.99% new shares faced quorum issues on Feb 6, 2026. Alongside this, the company advanced ATR-04 and ATR-12 and presented at multiple investor conferences. Today’s cancellation of the 2026 special meeting follows that proxy and quorum backdrop rather than adding new clinical or financial data.

Key Terms

phase 1b, phase 1/2, egfr inhibitor, fast track designation, +2 more

6 terms

phase 1b medical

"The ATR-12 program includes a Phase 1b clinical trial in adult Netherton..."

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

phase 1/2 medical

"ATR-04, Azitra's additional advanced program, utilizes another engineered strain... Phase 1/2..."

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

egfr inhibitor medical

"for the treatment of EGFR inhibitor ("EGFRi") associated rash."

An epidermal growth factor receptor (EGFR) inhibitor is a medicine that blocks a specific protein on some cancer cells that acts like a ‘on’ switch for growth; by turning that switch off, the drug can slow or stop tumor growth. Investors care because these drugs are often tied to clear clinical tests, targeted patient groups, patent-protected sales and regulatory decisions, so trial results, safety issues or approvals can sharply change a company’s value.

fast track designation regulatory

"Azitra has received Fast Track designation from the FDA for EGFRi associated rash..."

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

biotherapeutic products medical

"engineered proteins and topical live biotherapeutic products that includes a microbial library..."

Medicines made from living cells or materials they produce — such as proteins, antibodies, vaccines, cell therapies and gene therapies — rather than chemicals made in a factory. They matter to investors because they can command high prices and strong patent protection but also require lengthy testing, complex manufacturing and strict regulation, so clinical or production setbacks can sharply affect a company’s value.

artificial intelligence technical

"The platform is augmented by artificial intelligence and machine learning technology..."

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026.

About Azitra

Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Azitra's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of stockholder approval, statements about our clinical and preclinical programs and corporate and clinical/preclinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the timing of stockholder approval; the timing of clinical trials and their results as we may experience delays in the provision of results for ATR-12 and/or ATR-04 or, if we do, that such data may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 27, 2026. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact

Norman Staskey
Chief Financial Officer
staskey@azitrainc.com 

Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com 

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-cancellation-of-2026-special-meeting-of-stockholders-302705612.html

SOURCE Azitra, Inc.

FAQ

Why did Azitra (AZTR) cancel the March 6, 2026 special meeting of stockholders?

Azitra canceled the adjourned meeting after failing to achieve a necessary quorum for the session. According to Azitra, the meeting was originally set for February 6, 2026 and adjourned to March 6, 2026 due to insufficient shareholder participation; no replacement date was provided.

Does the cancellation of the AZTR special meeting affect Azitra's ATR-12 Phase 1b clinical trial timeline?

The cancellation does not explicitly change clinical timelines described in the announcement. According to Azitra, ATR-12 remains a Phase 1b program for adult Netherton syndrome patients; the company did not report any trial delays or modifications in this notice.

What does Azitra (AZTR) say about its ATR-04 program and regulatory status?

Azitra reports ATR-04 has received FDA Fast Track designation for EGFRi associated rash. According to Azitra, the ATR-04 program has an open IND in patients with EGFRi associated rash and targets a U.S. population of about 150,000 people.

How large is Azitra's microbial library and how does it support AZTR drug development?

Azitra's microbial library comprises approximately 1,500 bacterial strains used for candidate discovery. According to Azitra, the platform uses engineered proteins and AI/ML screening to analyze and predict drug‑like molecules from that strain library for topical live biotherapeutics.

What should AZTR shareholders do after the cancellation of the special meeting?

Shareholders should monitor company communications for any rescheduling or proxy updates and retain voting materials. According to Azitra, no new meeting date was announced in this release, so investors should check the investor relations site for further notices.